Adjuvant Pertuzumab and Herceptin IN Initial TherapY of Breast Cancer
E2190239
UNEXPLORED
APHINITY is a phase III clinical trial evaluating the addition of pertuzumab to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Adjuvant Pertuzumab and Herceptin IN Initial TherapY of Breast Cancer canonical | 2 |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.